9 articles with Centauri Therapeutics
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
Centauri Therapeutics Limited, an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announced the close of its £24 million GBP Series A investment round.
Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences
Centauri response by Dr Mike Westby, CEO of Centauri Therapeutics, to Dr Rick Bright, BARDA, Forbes article 10 May 19, “Building New Models To Support The Ailing Antibiotics Market”
Centauri Therapeutics (“Centauri”) is an immunotherapy company active in oncology and infectious diseases.
Centauri Therapeutics (“Centauri”), an immunotherapy company active in oncology and infectious diseases, announces that Mel Glossop, Head of Chemistry at Centauri, presented at the 4th Annual Advances in immune-Oncology Congress London, on 20 – 21 May.
Centauri Therapeutics to present at 29th European Congress of Clinical Microbiology & Infectious Diseases
Jennifer Schneider, PhD. Vice President, Business Development at Centauri Therapeutics, will be presenting during the “Therapeutics pipeline corner” session, at 12.15pm CET on 14 April 2019.